Assertio Holdings, Inc. Common Stock
ASRTAssertio Holdings, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for neurological and other specialized conditions. It provides products that address unmet medical needs, often through drug delivery mechanisms aimed at improving patient outcomes. The company operates in the United States and offers a portfolio of medications targeting areas such as pain management, neurology, and inflammation.
Company News
A federal class action lawsuit against Spectrum Pharmaceuticals alleges the company misled investors about its cancer treatment drug poziotinib's success, causing significant stock price decline after FDA concerns were revealed.
A federal class action lawsuit alleges Spectrum Pharmaceuticals misled investors about its cancer treatment drug poziotinib, causing significant stock price decline after FDA concerns were revealed.
A class action lawsuit has been filed against Assertio Holdings, Inc. (NASDAQ: ASRT) alleging that the company and its executives made false and misleading statements in the registration statement for its merger with Spectrum Pharmaceuticals, Inc. The lawsuit claims the statements overstated the strength of Indocin, downplayed the risk of generic...
Assertio Holdings, Inc. announced that it has granted 62,500 restricted stock units and 275,000 stock options to its newly-hired Senior Vice President, Chief Commercial Officer, Mary Pietryga, as an inducement to her employment.
Beam Therapeutics, a biotechnology company developing precision genetic medicines, has appointed Sravan K. Emany as its new Chief Financial Officer. Emany brings extensive experience in the life sciences industry and will help guide Beam's growth and capital allocation strategy.
